Trial reportBMC nephrology2020
Nicotinamide riboside with pterostilbene (NRPT) increases NAD
Trial report in BMC nephrology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Double-blind, Placebo-controlled, Stepwise Study of the Pharmacokinetics, Pharmacodynamics & Safety of Escalating Doses of Basis (Nicotinamide Riboside and Pterostilbene) in Patients With Acute Kidney Injury (AKI)
Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery.A Randomized Controlled Pilot Study
Who cites it
25 citing papers in PubMed, 42 citations in OpenAlex.
- Effect of nicotinamide riboside on airway inflammation in COPD: a randomized, placebo-controlled trial.Nature aging · 2024Trial
- NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.Nature communications · 2023Trial
- The therapeutic horizon of acute kidney injury in critical care: exploring pathology, promises, pitfalls, and progress.Current opinion in critical care · 2025Review
- The role of NADnpj metabolic health and disease · 2025Review
- New drugs for acute kidney injury.Journal of intensive medicine · 2025Review
- NADCell communication and signaling : CCS · 2024Review
- NAD deficiency contributes to progressive kidney disease in HIV-nephropathy mice.American journal of physiology. Renal physiology · 2024Article
- Program with last minute abstracts of the Padua Days on Muscle and Mobility Medicine, 27 February - 2 March, 2024 (2024Pdm3).European journal of translational myology · 2024Article
- Article
- Five Padua days on muscle and mobility medicine (2024Pdm3) 27 February - 2 March, 2024 at Hotel Petrarca, Thermae of Euganean Hills, Padua, and San Luca Hall, Prato della Valle, Padua, Italy.European journal of translational myology · 2023Article
- Lactate: A Theranostic Biomarker for Metabolic Psychiatry?Antioxidants (Basel, Switzerland) · 2023Review
- Nicotinamide Riboside, a Promising Vitamin BMolecules (Basel, Switzerland) · 2023Review
- What is really known about the effects of nicotinamide riboside supplementation in humans.Science advances · 2023Review
- NAD+ Biosynthesis Impairment and Acute Kidney Injury after Major Vascular Surgery.Antioxidants (Basel, Switzerland) · 2023Article
- NADNature metabolism · 2023Article
- Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan.Nutrients · 2023Review
- Roles of NADInternational journal of molecular sciences · 2022Review
- Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction.JACC. Basic to translational science · 2022Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundPreclinical studies have identified both NAD
methodsWe conducted a randomized, double-blind, placebo-controlled study of escalating doses of NRPT in 24 hospitalized patients with AKI. The study was comprised of four Steps during which NRPT (5 subjects) or placebo (1 subject) was given twice a day for 2 days. NRPT dosing was increased in each Step: Step 1250/50 mg, Step 2500/100 mg, Step 3750/150 mg and Step 41,000/200 mg. Blood NAD
resultsAKI resulted in a 50% reduction in whole blood NAD
conclusionNRPT increases whole blood NAD
trial registrationNCT03176628 , date of registration June 5th, 2017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.